AMCP submitted comments to CMS in response to its proposed rule for technical changes to the Medicare Prescription Drug Benefit Program. AMCP offered comments on the following areas of the proposed rule: drug management programs, Medication Therapy Management, benefit design & utilization management, health information technology & data interoperability, and fraud, waste, & abuse.
On November 16th, 2017, CMS released a much anticipated proposed rule that amends regulations for Medicare Part C and Medicare Part D to implement provisions of the Comprehensive Addiction and Recovery Act (CARA) and the 21st Century Cures Act. The proposed rule also makes changes to improve program quality, accessibility, and affordability and also adopts the updated NCPDP script standard for electronic prescribing.
AMCP CEO Blog: Who says Congress can’t get anything done…and with bipartisan support to boot? With impressive speed and purpose, the House and Senate overwhelmingly passed the 21st Century Cures Act in the waning days of the 114th Congress.
On May 23, 2013, CMS finalized a rule that will allow for certain MTM activities and fraud reduction activities to count toward Medicare Part D and Medicare Advantage medical loss ratio (MLR).
The Centers for Medicare and Medicaid Services (CMS), will allow for certain MTM activities and fraud reduction activities to count toward Medicare Part D and Medicare Advantage medical loss ratio (MLR)